Paul R. Lockman

Department of Basic Pharmaceutical Sciences, West Virginia University

Research Area

Biography

Dr. Lockman earned his B.S. in Nursing from West Texas A&M University, after which he practiced in intensive care, clinical toxicology and emergency medicine, then went on to earn his Ph.D. (Pharmaceutical Sciences) at Texas Tech University Health Sciences Center. Dr. Lockman was an Associate Professor and Associate Dean for Outcomes Assessment and Accreditation at Texas Tech University before transitioning to West Virginia University. Currently, Dr. Lockman is the Mylan Endowed Chair of Pharmacology at West Virginia University School of Pharmacy. He also serves as an Assistant Vice of Experimental Director for Translational Research at West Virginia University . Dr. Lockman’s primary research focus is on understanding why chemotherapy has limited distribution, and ultimately fails in brain metastases of breast cancer.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 3	2021

Other Publications

Article	Year
Novel treatment strategies for brain tumors and metastases. Pharmaceutical patent analyst\| PubMed ID: 24998288	2014
Complex issues affecting student pharmacist debt. American journal of pharmaceutical education\| PubMed ID: 25258436	2014
A novel preclinical method to quantitatively evaluate early-stage metastatic events at the murine blood-brain barrier. Cancer prevention research (Philadelphia, Pa.)\| PubMed ID: 25348853	2015
Report of the 2013-2014 Academic Affairs Committee. American journal of pharmaceutical education\| PubMed ID: 25657388	2014
Molecular determinants of blood-brain barrier permeation. Therapeutic delivery\| PubMed ID: 26305616	2015
NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer. BMC cancer\| PubMed ID: 26463521	2015
Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer. Clinical & experimental metastasis\| PubMed ID: 26944053	2016
Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 27245829	2016
Semi-automated rapid quantification of brain vessel density utilizing fluorescent microscopy. Journal of neuroscience methods\| PubMed ID: 27321229	2016
Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study. Pharmaceutical research\| PubMed ID: 27528392	2016
Quantitative Fluorescence Microscopy Measures Vascular Pore Size in Primary and Metastatic Brain Tumors. Cancer research\| PubMed ID: 27815391	2017
Identification of Novel Agents for the Treatment of Brain Metastases of Breast Cancer. Current cancer drug targets\| PubMed ID: 27903215	2017
Permeability across a novel microfluidic blood-tumor barrier model. Fluids and barriers of the CNS\| PubMed ID: 28114946	2017
Inhibition of VEGF and Angiopoietin-2 to Reduce Brain Metastases of Breast Cancer Burden. Frontiers in pharmacology\| PubMed ID: 28443023	2017
A mouse Model of Focal Vascular Injury Induces Astrocyte Reactivity, Tau Oligomers, and Aberrant Behavior. Archives of neuroscience\| PubMed ID: 28758136	2017
Trastuzumab distribution in an and model of brain metastases of breast cancer. Oncotarget\| PubMed ID: 29137378	2017
Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Ca... Pharmaceutical research\| PubMed ID: 29368289	2018
Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases. Pharmacological research\| PubMed ID: 29604436	2018
An Effective Approach to Teaching Pharmacogenomics in the First Year of Pharmacy Curriculum. American journal of pharmaceutical education\| PubMed ID: 30425398	2018
Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis. Oncogene\| PubMed ID: 30467378	2019
Permeability changes and effect of chemotherapy in brain adjacent to tumor in an experimental model of metastatic brain tumor from breast cancer. BMC cancer\| PubMed ID: 30526520	2018
Long non-coding RNA FAM83H-AS1 is regulated by human papillomavirus 16 E6 independently of p53 in cervical cancer cells. Scientific reports\| PubMed ID: 30842470	2019
Targeting the Blood-Brain Barrier to Prevent Sepsis-Associated Cognitive Impairment. Journal of central nervous system disease\| PubMed ID: 31007531	2019
Development of a Cx46 Targeting Strategy for Cancer Stem Cells. Cell reports\| PubMed ID: 31018124	2019
Improving CNS Delivery to Brain Metastases by Blood-Tumor Barrier Disruption. Trends in cancer\| PubMed ID: 31421906	2019
MiR-34a Interacts with Cytochrome c and Shapes Stroke Outcomes. Scientific reports\| PubMed ID: 32094435	2020
Drug resistance occurred in a newly characterized preclinical model of lung cancer brain metastasis. BMC cancer\| PubMed ID: 32264860	2020